| 1950 |
Commenced sales of pharmaceutical drugs for medical use |
| 1950 |
Established Hitachi Chemical Co., Ltd. (formerly known as) and began sales of medical pharmaceuticals. |
| 1950 |
Japan Chemifa Co., Ltd. was founded in 1950. |
| 1951 |
Opened a factory in Hatanaka, Shibuya-ku, Tokyo |
| 1957 |
Introduced 'Timpanol' from Italy for the first time, began overseas transactions, relocated headquarters to Bunkyo-ku, Tokyo |
| 1957 |
First introduced "Timpano" from Italy and started overseas transactions: relocated headquarters to Bunkyo-ku, Tokyo. |
| 1960 |
Opened a grass processing plant in Misato City, Saitama Prefecture |
| 1969 |
Made Nippon Yakuhin Kogyo Co., Ltd. a subsidiary (currently a consolidated subsidiary) |
| 1970 |
Changed company name to Nippon Chemifa Co., Ltd. |
| 1971 |
Listed shares on the Second Section of the Tokyo Stock Exchange |
| 1973 |
Established a research laboratory within the grass processing plant |
| 1975 |
Relocated headquarters to Chiyoda-ku, Tokyo (current location) |
| 1976 |
Reclassified to the First Section of the Tokyo Stock Exchange, entered the clinical diagnostic reagent business, and established Japan Sofar Sim Co., Ltd. (currently a related company) |
| 1976 |
Reclassified to the First Section of the Tokyo Stock Exchange: entered the clinical diagnostic reagent business: established Japan Sofarshim Co., Ltd. (currently a subsidiary). |
| 1977 |
Opened the Ibaraki factory (now the Japan Pharmaceutical Industry Tsukuba Factory) in Maki District, Ibaraki Prefecture (now Chikusei City). |
| 1983 |
Founded Shapuro Co., Ltd. (currently dormant) and entered the cosmetics and health food sector. |
| 1986 |
Made the Compound Safety Research Institute Co., Ltd. a subsidiary (now a consolidated subsidiary). |
| 1988 |
Released the alkali chemotherapy agent 'Uralit-U'. |
| 1988 |
Released the alkali chemotherapy agent "Uralit-U". |
| 1992 |
'Uralit tablets' released. |
| 1992 |
Released "Uralit tablets". |
| 1993 |
Released the analgesic and anti-inflammatory drug 'Soretone tablets'. |
| 1995 |
Released the hypertension treatment drug 'Carban tablets'. |
| 2000 |
Fully entered the generic pharmaceutical business. |
| 2000 |
Since 2000, generic pharmaceuticals have been positioned as the core of the business, with development, manufacturing, and sales handled consistently within the group. |
| 2001 |
Released the allergy-specific IgE measurement device 'DiaPack2000' and the dedicated reagent 'Oriton IgE: Chemifa'. |
| 2002 |
Commenced a comprehensive business partnership with Ranbaxy Laboratories Limited (headquartered in India). |
| 2004 |
Commenced a capital and business partnership with Nihon Chouzai Co., Ltd. |
| 2005 |
Introduced the lipid metabolism improvement agent 'NC-2400' to Cerenis, and merged Nippon Pharmaceutical Industry Co., Ltd. into a 50:50 joint company with Ranbaxy. |
| 2005 |
Derived the lipid metabolism improving agent "NC-2400" to Cerenis: merged Japan Pharmaceutical Industry Co., Ltd. into a 50:50 joint venture with Ranbaxy. |
| 2009 |
Ended the comprehensive business partnership with Ranbaxy, repurchased 50% of Nippon Pharmaceutical Industry Co., Ltd.'s shares, and converted the joint venture into a subsidiary. |
| 2009 |
Dissolved the comprehensive business alliance with Ranbaxy: repurchased 50% of Japan Pharmaceutical Industry Co., Ltd.'s shares and made the joint venture a subsidiary. |
| 2010 |
Made Nippon Pharmaceutical Industry Co., Ltd. a 100% subsidiary, absorbed the Ibaraki factory into it, and ended the business partnership with Nihon Chouzai Co., Ltd. |
| 2010 |
Made Japan Pharmaceutical Industry Co., Ltd. a 100% subsidiary: absorbed the Ibaraki plant into Japan Pharmaceutical Industry Co., Ltd. and dissolved the business alliance with Japan Pharmacy Co., Ltd. |
| 2012 |
Released the allergy-specific IgE measurement device 'DiaPack3000'. |
| 2014 |
Completed Building 3 of the Nippon Pharmaceutical Industry Co., Ltd. Tsukuba Factory. |
| 2015 |
Established Nippon Chemiphar Vietnam Co., Ltd. (NC-VN) in Vietnam. |
| 2017 |
NC-VN completed a manufacturing plant in Binh Son Province, Vietnam, and opened a West Japan logistics center in Kobe, Hyogo Prefecture, establishing a two-site east-west system. |
| 2017 |
NC-VN completed a manufacturing plant in Binh Son Province, Vietnam: opened a West Japan logistics center in Kobe City, Hyogo Prefecture, establishing a two-site east-west system. |
| 2018 |
NC-VN Vietnam factory began exporting to Japan. |
| 2019 |
Acquired the oral intestinal lavage agent 'PicoPrep oral formulation' from Feling Pharma Co., Ltd. |
| 2020 |
Launch of allergy screening equipment and reagents "Drop Screen", signing of a license agreement with Delta-Fly Pharma Co., Ltd. regarding the tumor microenvironment improving agent "DFP-17729", transfer of sales of the macrolide antibiotic formulation "Clarithid" from Mairan EPD LLC, and initiation of patient enrollment for Phase I and II trials of the tumor microenvironment improving agent "DFP-17729". |
| 2020 |
Launch of allergy screening equipment and reagents "Drop Screen", signing of a license agreement with Delta-Fly Pharma Co., Ltd. regarding the tumor microenvironment improving agent "DFP-17729", transfer of sales of the macrolide antibiotic formulation "Clarithid" from Mairan EPD LLC, and initiation of patient enrollment for Phase I and II trials of the tumor microenvironment improving agent "DFP-17729". |
| 2021 |
Transition to Phase II trial of the tumor microenvironment improving agent "DFP-17729", signing of a joint research and development agreement and option contract with Dai Nippon Sumitomo Pharma regarding the opioid delta receptor agonist "NC-2800", and commencement of Phase I in July. |
| 2021 |
Transition to Phase II trial of the tumor microenvironment improving agent "DFP-17729", signing of a joint research and development agreement and option contract with Dai Nippon Sumitomo Pharma regarding the opioid delta receptor agonist "NC-2800", and commencement of Phase I in July. |
| 2022 |
Signed a license agreement with Delta-Fly Pharma Co., Ltd. regarding the anticancer candidate compound "DFP-14323". |
| 2023 |
Signed a license agreement with a Chinese company for the XOR inhibitor "NC-2500", and a sales agreement with Fujifilm Medical Corporation regarding "Drop Screen". |
| 2023 |
Signed a license agreement with a Chinese company for the XOR inhibitor "NC-2500", and a sales agreement with Fujifilm Medical Corporation regarding "Drop Screen". |
| 2025 |
Released the authorized generic (AG) "Glimepiride tablet NC" of the sulfonylurea oral hypoglycemic agent Amaryl® tablets manufactured and sold by Sanofi, and initiated patient enrollment for Phase II and Phase III trials of the tumor microenvironment improving agent "DFP-17729". |
| 2025 |
Released the authorized generic (AG) "Glimepiride tablet NC" of the sulfonylurea oral hypoglycemic agent Amaryl® tablets manufactured and sold by Sanofi, and initiated patient enrollment for Phase II and Phase III trials of the tumor microenvironment improving agent "DFP-17729". |
